Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Latest filing published 17 May 2022 for NEKTAR THERAPEUTICS, €17k. Read the official filing
Filing timeline
BuySaleJohn Northcott
Insider track record
Disclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
John Northcott: trading record in brief
All filings by John Northcott on record concern Nektar Therapeutics, in the capacity of senior executive. In total, 6 filings cover trades dated from 17 May 2021 to 16 May 2022.
No open-market purchase appears, only 5 sales worth €299k. Other entries cover 1 share grant. 2022 to date brings no purchases and 2 sales.
The latest filing, published on 17 May 2022, reports an open-market sale of €17k in Nektar Therapeutics. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John Northcott
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
4,592 shares@ US$3.950.0007% mcap3.0% of flowCommon StockSEC:0001209191-22-029900:0
4,852 shares@ US$10.950.0020% mcap8.1% of flowCommon StockSEC:0001209191-22-011437:0
37,800 shares0Common StockSEC:0001209191-21-070691:0
6,061 shares@ US$13.1623.5% of flowCommon StockSEC:0001209191-21-065221:0
6,192 shares@ US$13.8324.3% of flowCommon StockSEC:0001209191-21-052385:0
6,085 shares@ US$18.3030.7% of flowCommon StockSEC:0001209191-21-034186:0
6 of 6 declarations
